2016
DOI: 10.15171/jnp.2017.17
|View full text |Cite
|
Sign up to set email alerts
|

Mycophenolate mofetil for the treatment of Henoch-Schönlein purpura nephritis; current knowledge and new concepts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…Henoch-Schönlein purpura (HSP) nephritis (HSPN) is one of the major clinical manifestations (renal injury) and primary cause of mortality and morbidity in HSP [1]. Within 4-6 weeks after initial disease onset, approximately 30-50% of children with HSP progress to HSPN [2], which accounts for 1.8-3% of children with chronic kidney disease and may result in chronic renal failure in 11-38% of patients with severe manifestations and pathologic changes in long-term follow-up [3]. e severity of renal injury is the key factor determining the prognosis of HSPN [1].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Henoch-Schönlein purpura (HSP) nephritis (HSPN) is one of the major clinical manifestations (renal injury) and primary cause of mortality and morbidity in HSP [1]. Within 4-6 weeks after initial disease onset, approximately 30-50% of children with HSP progress to HSPN [2], which accounts for 1.8-3% of children with chronic kidney disease and may result in chronic renal failure in 11-38% of patients with severe manifestations and pathologic changes in long-term follow-up [3]. e severity of renal injury is the key factor determining the prognosis of HSPN [1].…”
Section: Introductionmentioning
confidence: 99%
“…erefore, great efforts are in urgent need for renal injury controlling in children with HSPN. However, till now, there is no absolute consensus for the best management of severe HSPN, and the most effective treatment remains controversial [3]. Furthermore, corticosteroids, immunosuppressants, and anticoagulants have potential side effects, such as oncogenesis, myelosuppression, hemorrhagic cystitis, and interstitial pneumonia [4].…”
Section: Introductionmentioning
confidence: 99%